Subcutaneous Rapid-acting Insulin Analogs for Diabetic Ketoacidosis.

Abstract

Diabetic ketoacidosis (DKA), characterized by hyperglycemia, metabolic acidosis, and ketosis, is a serious complication of diabetes mellitus. Treatment focuses on fluid restoration, correction of hyperglycemia, and inhibition of ketogenesis. Insulin is considered a fundamental component of DKA treatment as it promotes the peripheral tissues' utilization of glucose in peripheral tissues by reducing hepatic gluconeogenesis and suppressing ketogenesis.1.